Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Editas Medicine, Inc. - Common Stock
(NQ:
EDIT
)
3.340
-0.120 (-3.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
The 3 Best Gene Editing Stocks to Buy in July 2024
↗
July 08, 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
Via
InvestorPlace
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
↗
June 26, 2024
Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks.
Via
InvestorPlace
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
↗
June 25, 2024
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions.
Via
InvestorPlace
Unveiling 5 Analyst Insights On Editas Medicine
↗
June 18, 2024
Via
Benzinga
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
June 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
↗
May 30, 2024
Via
Benzinga
The Latest Analyst Ratings For Editas Medicine
↗
February 29, 2024
Via
Benzinga
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 2/28
February 28, 2024
Via
Investor Brand Network
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
June 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential
↗
May 30, 2024
Invest in these undervalued stocks poised for long-term growth as Wall Street shifts focus to broader market gains.
Via
InvestorPlace
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
May 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
May 10, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Earnings Outlook For Editas Medicine
↗
February 27, 2024
Via
Benzinga
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
↗
May 09, 2024
The company has great potential if and when it enters the commercial stage.
Via
The Motley Fool
EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024
↗
May 08, 2024
EDIT stock results show that Editas Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Editas Medicine Announces First Quarter 2024 Results and Business Updates
May 08, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
May 02, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
May 01, 2024
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
April 22, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
↗
March 07, 2024
The company now has a chance to get its lead program out the door a bit sooner.
Via
The Motley Fool
1 Beaten-Down Stock With 55% Upside, According to Wall Street
↗
March 04, 2024
The biotech has bounced back some in the past year.
Via
The Motley Fool
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
↗
March 02, 2024
The clinical-stage genome editing company dropped a couple of important announcements for shareholders.
Via
The Motley Fool
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
↗
February 28, 2024
The company reported in-line sales for the fourth quarter, but shares soared by double digits.
Via
Investor's Business Daily
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
February 28, 2024
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
Via
Benzinga
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
↗
February 28, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday.
Via
Benzinga
Topics
Stocks
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
February 28, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
February 21, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
January 31, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
2 Under-the-Radar Stocks With Incredible Upside Potential
↗
January 28, 2024
It's also important to consider their downsides.
Via
The Motley Fool
Could Editas Medicine Become the Next CRISPR Therapeutics?
↗
January 21, 2024
The similarities between the pair are striking, but it might not be enough.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
